Trial Profile
A PHASE 1, RANDOMIZED, PLACEBO-AND POSITIVE-CONTROLLED CROSSOVER STUDY TO DETERMINE THE EFFECT OF SINGLE-DOSE PF-04965842 ON QTC INTERVAL IN HEALTHY VOLUNTEERS
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Abrocitinib (Primary) ; Moxifloxacin
- Indications Atopic dermatitis
- Focus Adverse reactions
- Sponsors Pfizer
- 11 Oct 2018 Status changed from recruiting to completed.
- 04 Oct 2018 Planned End Date changed from 21 Sep 2018 to 1 Oct 2018.
- 04 Oct 2018 Planned primary completion date changed from 21 Sep 2018 to 1 Oct 2018.